logo
What to Expect From Diamondback Energy's Next Quarterly Earnings Report

What to Expect From Diamondback Energy's Next Quarterly Earnings Report

Yahoo15-07-2025
Midland, Texas-based Diamondback Energy, Inc. (FANG) operates as an independent oil and gas exploration & production company, with its primary focus on the Permian Basin. Valued at $42.2 billion by market cap, the upstream operator focuses on growth through a combination of acquisitions and active drilling activities.
The energy giant is expected to announce its second-quarter results after the market closes on Monday, Aug. 4. Ahead of the event, analysts expect FANG to report a profit of $2.57 per share, down 43.1% from $4.52 per share reported in the year-ago quarter. While the company has missed the Street's bottom-line estimates in one of the past four quarters, it has surpassed the projections on three other occasions.
Palantir Just Launched Warp Speed for Warships. Does That Make PLTR Stock a Buy?
This Analyst Just Doubled His Price Target on AMD Stock
How High Can Nvidia Stock Go as Jensen Huang Heads to China?
Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today!
For the full fiscal 2025, FANG is expected to report an EPS of $12.96, down 21.8% from $16.57 reported in fiscal 2024. In fiscal 2026, its earnings are expected to drop further by 13% year-over-year to $11.28 per share.
FANG stock has plummeted 30.5% over the past 52 weeks, significantly underperforming the S&P 500 Index's ($SPX) 11.6% gains and the Energy Select Sector SPDR Fund's (XLE) 2.6% dip during the same time frame.
Despite reporting better-than-expected financials, Diamondback Energy's stock prices observed a marginal drop in the trading session after the release of its Q1 results on May 5. The company's topline for the quarter soared 81.8% year-over-year to $4.05 billion, exceeding the consensus estimates by a staggering 13.1%. Meanwhile, its adjusted EPS came in at $4.54, 11% ahead of the Street expectations.
However, the company reduced its full-year production and capital expenditure guidance, which likely didn't impress investors.
Nevertheless, FANG maintains a consensus 'Strong Buy' rating overall. Of the 28 analysts covering the stock, opinions include 23 'Strong Buys,' three 'Moderate Buys,' and two 'Holds.' Its mean price target of $181.89 suggests a 28.1% upside potential from current price levels.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Handlery Union Square Hotel Awarded 4-Key Green Key Global Certification
Handlery Union Square Hotel Awarded 4-Key Green Key Global Certification

Yahoo

time27 minutes ago

  • Yahoo

Handlery Union Square Hotel Awarded 4-Key Green Key Global Certification

Nearly Century-Old Family Hotel Company Showcases Environmental Leadership with Comprehensive Sustainability Program SAN FRANCISCO, July 22, 2025 (GLOBE NEWSWIRE) -- Handlery Union Square Hotel has earned a prestigious 4-Key rating from Green Key Global, one of the hospitality industry's leading sustainability certification providers. The certification recognizes the hotel's comprehensive environmental programs and positions the nearly 100-year-old family business as a leader in sustainable hospitality practices. The 4-Key Green Key Global certification signifies "a property that has shown national industry leadership and commitment to protecting the environment through wide-ranging policies and practices." "Achieving this certification validates what we've been doing for years – operating responsibly while providing exceptional guest experiences," said Jack Handlery, General Manager of Handlery Union Square Hotel. "As California's oldest family-owned hotel company, we understand the importance of preserving our environment for future generations." The three-month certification process involved extensive documentation and an independent audit of the hotel's environmental practices across multiple categories, including waste minimization, energy efficiency, water conservation, and sustainable purchasing policies. "Our team has embraced these practices as part of our daily operations," added Handlery. "This certification is a recognition of our ongoing commitment to environmental responsibility." Leadership Team Expansion Complementing the sustainability certification, Handlery Hotels has welcomed Brenda Alberigi as Director of Sales. Alberigi most recently served as Director of Sales for Archer Hotel Napa and has over 28 years of experience in the Bay Area hospitality market. "More travelers and corporate clients are prioritizing sustainability in their accommodation choices," said Alberigi. "This Green Key certification provides tangible proof of our environmental commitment and helps differentiate us in the marketplace." About Handlery Hotels Founded by Harry Handlery in 1928, Handlery Hotels is California's oldest family-owned hotel company, serving guests for nearly 100 years. Two premier properties welcome guests visiting both northern and southern California: Handlery Union Square Hotel in San Francisco and Handlery Hotel San Diego. Both hotels feature heated outdoor pools, on-site parking, and prime locations near major attractions. Frequent guests can take advantage of the Handlery Rewards program, which offers exclusive perks and complimentary offers to members. For more information, visit The Green Key Global certification adds to Handlery's recent recognitions, including the 2025 TripAdvisor Travelers' Choice award. Media please note: For interview requests and photos, please contact Beatrice Kilat at (415) 745-9109 or beatrice@ Media Contact:Beatrice KilatLandis Communications

US Treasuries Edge Higher as Bessent Offers Support for Powell
US Treasuries Edge Higher as Bessent Offers Support for Powell

Yahoo

time27 minutes ago

  • Yahoo

US Treasuries Edge Higher as Bessent Offers Support for Powell

(Bloomberg) -- Treasuries rose, reversing earlier losses, as Treasury Secretary Scott Bessent said he sees no reason for Jerome Powell to step down as Federal Reserve chair. Why the Federal Reserve's Building Renovation Costs $2.5 Billion Salt Lake City Turns Winter Olympic Bid Into Statewide Bond Boom Milan Corruption Probe Casts Shadow Over Property Boom How San Jose's Mayor Is Working to Build an AI Capital Yields on Treasuries fell about 3 basis points across maturities. The rate on the two-year, which is particularly sensitive to changes in monetary policy, fell to 3.83%, the lowest level since July 3. Powell's future has become a key issue for bond investors as the Fed chief has come under fire from President Donald Trump for holding interest rates steady while waiting to see if trade tariffs impact inflation. Bessent, speaking Tuesday on Fox Business, however, said if Powell wants, he should stay in the post until his term ends in May. 'There could be some relief, at least for the longer end of the curve, that Bessent supports Powell remaining chair until the end of his term,' said Zachary Griffiths, head of investment-grade and macroeconomic strategy at CreditSights. With few major US economic data releases, and Fed speakers in a blackout period ahead of next week's meeting, traders are shifting their attention to next week's Treasury Department announcement of projected auction sizes for the quarter, Griffiths said. 'Growing comfort that Treasury will be maintaining nominal coupon auctions at current sizes for the foreseeable future may be assuaging supply/demand imbalance concerns,' he said. Benchmark 10-year notes extended gains to a fifth day with the yield dipping to 4.35%, about 13 basis points lower than its level a week ago. Powell Pressure Trump and some members of his administration view Powell as a hurdle to lower borrowing costs as they seek to refinance trillions in upcoming debt. Treasuries fell sharply last week after headlines flashed that the president was planning to fire Powell, a claim quickly denied by Trump. Deutsche Bank AG strategists estimated Powell's ousting would drive 30-year yields up by more than a half a percentage point. The yield stood at about 4.91% on Tuesday in New York. The strategists said the clearest hedge against risks to the Fed's independence — and a situation in which US government spending consumes monetary policy — are bets on steeper yield curves. (Recasts with Bessent comments.) Elon Musk's Empire Is Creaking Under the Strain of Elon Musk A Rebel Army Is Building a Rare-Earth Empire on China's Border Thailand's Changing Cannabis Rules Leave Farmers in a Tough Spot How Starbucks' CEO Plans to Tame the Rush-Hour Free-for-All What the Tough Job Market for New College Grads Says About the Economy ©2025 Bloomberg L.P. Sign in to access your portfolio

Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot
Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot

Yahoo

time27 minutes ago

  • Yahoo

Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the top high-return penny stocks to buy now. On July 7, Leerink Partners resumed coverage of the stock with an 'Outperform' rating and a $5 price target. The research firm remains confident about the company's long-term prospects following its pivot from an antibody discovery platform to one that develops its internal pipeline. A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company. Leerink Partners is especially bullish about the company's upcoming programs ABCL575, an OX40L antagonist targeting atopic dermatitis, and ABCL635, an NK3R antagonist for vasomotor symptoms. The two programs are scheduled to enter Phase 1 clinical trials in the third quarter of 2025. The research firm also pointed out that AbCellera's existing antibody discovery collaborations are well-positioned to deliver long-term value. It expects the company to benefit from milestone payments and royalties as it leverages antibody capabilities towards a pipeline focused on validated targets. AbCellera Biologics Inc. (NASDAQ:ABCL) is a biotechnology company that focuses on discovering and developing antibody-based medicines. It leverages a proprietary, AI-powered technology platform to search, decode, and analyze natural immune systems, identifying antibodies that can be developed into potential drugs. While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store